AYTU logo

AYTU BIOPHARMA INC

AYTUNASDAQ
πŸ† #4607 by market capEarnings Nov 16US Equity
$1.97β–² $0.07 (+3.68%)
πŸŒ… Pre-market$1.96β–Ό 0.51%Regular close Β· extended-hours price shown
πŸ””
Track AYTU
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.7%
7dβ–² 0.3%
14dβ–² 0.5%
30dβ–Ό 8.4%
ytdβ–Ό 24.5%
1yβ–Ό 9.2%
🏦Market Cap
$21M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-13.3%
Declining
πŸ“ŠGross Margin
64.0%
High
πŸ’΅FCF Margin
5.7%
Moderate
βš–οΈP/S Ratio
0.4x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.90 – $1.97
52-Week Range
$1.80 – $3.07
Volume (shares)
20,214
Avg Volume (shares)
β€”
Shares Outstanding
10.9M
Next Earnings
2026-11-16

Fundamentals Snapshot

Annual Revenue
$58M
Last Q Revenue
$16M
P/E Ratio
-1.4
P/S Ratio
0.4x
EPS (TTM)
$-1.16
Dividend Yield
0.00%
Dilution (1yr)
+22.7%
AYTU logo

AYTU BIOPHARMA INC

AYTU
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$58Mβ–Ό βˆ’13.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.0%β–Ό βˆ’7.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$8Mβ–² +6.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$3Mβ–Ό βˆ’163.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.3Mβ–² +22.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8Mβ–² +$1M YoY
StockOtter Β· stockotter.space

About AYTU BIOPHARMA INC

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Zacks Investment ResearchΒ·21d ago

Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?

ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.

Seeking AlphaΒ·Sep 22

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Zacks Investment ResearchΒ·Sep 22

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.

AccesswireΒ·Sep 22

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6 million in fiscal 2

AccesswireΒ·Sep 16

Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system dise

Defense WorldΒ·Aug 26

AWM Investment Company Inc. Invests $1.33 Million in Aytu BioPharma Inc. $AYTU

AWM Investment Company Inc. bought a new stake in Aytu BioPharma Inc. (NASDAQ: AYTU) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). Th